Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 14 (Reuters) — Verastem Inc: Verastem Oncology Announces Planned Chief Executive Officer Transition And Succession Plan Verastem - Daniel Paterson To Retire As President And Ceo, Will Remain As Advisor And Board Member Verastem - Appoints Michael P. Bailey As President And Ceo Effective January 1, 2027 Source text
Verastem says Daniel Paterson will retire as president and CEO and remain as an advisor and board member.
Verastem named Michael P. Bailey president and CEO, effective Jan. 1, 2027, succeeding Daniel Paterson, who will retire. Bailey has served on Verastem’s board since May 2026; he previously ran AVEO Pharmaceuticals as president and CEO from 2015. Paterson will remain an advisor and continue as a board member. Disclaimer
For best results when printing this announcement, please click on link below: Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan Accomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem’s commercial business and lead pipeline asse